Background: Allopurinol is the most commonly used urate-lowering therapy, with rare but potentially fatal adverse effects. The study population included individuals aged 40 years who had a record of hyperuricaemia (serum urate level >357 mol/L for women and >416 mol/L for men) between January …
READ FULL ARTICLE
From ard.bmj.com